This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • B. Riley Securities analyst Kalpit Patel initiated coverage on ArriVent BioPharma, Inc. AVBP with a Buy rating and announced a price target of $37. ArriVent BioPharma shares closed at $19.60 on Wednesday. See how other analysts view this stock.
  • Goldman Sachs analyst Noah Poponak initiated coverage on Amentum Holdings, Inc. AMTM with a Neutral rating and announced a price target of $21. Amentum Holdings shares closed at $19.03 on Wednesday. See how other analysts view this stock.
  • Morgan Stanley analyst Judah Frommer initiated coverage on Celldex Therapeutics, Inc. CLDX with an Overweight rating and announced a price target of $46. Celldex Therapeutics shares closed at $19.95 on Wednesday. See how other analysts view this stock.
  • JP Morgan analyst Detlef Winckelmann initiated coverage on International Paper Company IP with an Overweight rating and announced a price target of $59. International Paper shares closed at $52.62 on Wednesday. See how other analysts view this stock.
  • Scotiabank analyst Patrick Colville initiated coverage on Microsoft Corporation MSFT with a Sector Outperform rating and announced a price target of $470. Microsoft shares closed at $387.82 on Wednesday.  See how other analysts view this stock.

Considering buying MSFT stock? Here’s what analysts think:

Today's Best Finance Deals

Read This Next:

Photo: Shutterstock

AMTM Logo
AMTMAmentum Holdings Inc
$22.56-0.57%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
Not Available
Growth
Not Available
Quality
Not Available
Value
31.29
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Comments
Loading...